Eli Lilly Announces Results From New Analysis Showing Zepbound 10 Mg And 15 Mg, Dual GIP And GLP-1 Receptor Agonist, Delivered Greater Weight Loss Than Wegovy HD In Adults With Obesity
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesityParticipants receiving Zepbound 15 mg had more than three times the odds of achieving at least 20% body-weight
Eli Lilly's weight loss medicine Zepbound worked better than a competitor's drug in a study. This suggests the company may be winning in a growing market that many people care about.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.